legochem biosciences announces

signing of both license agreement and mou

for legochem’s antibody drug conjugate 
with fosun pharma

daejeon and shanghai, august 18, 2015

legochem biosciences (141080ks) today announced that they have signed a license and commercialization agreement (the agreement) with fosun pharma (sh: 600196, hk: 02196) on august 17th. this agreement is no more than krw 20 billion for one of legochem’s next generation antibody-drug conjugate (the product) products and related technology for the greater china market. two companies additionally signed a memorandum of understanding (mou) for three other adc targets.

antibody-drug conjugate (adc) is mostly used as a next-generation anticancer drug that has gained wide attention in recent years. it is a unique combination of a precise and targeted monoclonal antibody, a linker, and a potent cytotoxic agent, and are designed to deliver potent anticancer agents to tumors in a targeted manner.

the product is legochem’s first and most advanced internally developed adc product with an undisclosed antibody targeting at multiple indications in cancer. fosun pharma will further develop the product in the greater china region.

at the prior ceremony for signing held in fosun pharma in shanghai, dr. yong-zu kim, ceo of legochem, mr. yifang wu, president of fosun pharma development and svp of fosun pharma group, discussed further collaboration between two companies.

mr. yifang wu said, “after evaluating multiple adc technologies from the us, eu and china, we believe that legochem is one of the leading second generation adc technology hubs, and we are pleased to announce that the first collaboration is now in place between fosun pharma and legochem”. he further added, “as a second step, we signed a mou for creating a possible collaboration room for both parties on additional adcs using several antibodies of henlius, fosun pharma’s one of the subsidiaries”. mr. wu also mentioned, “we are considering to partner with legochem because legochem’s pipeline programs fit to fosun pharma’s strategy especially in terms of innovation and to move forward to the global market together”.

dr. yong-zu kim, ceo of legochem, said: “we are excited to initiate this opportunity which proves that legochem’s adc technology is now globally recognized, and further allows legochem to broaden and accelerate other ongoing discussion with partners from the us, europe, and japan.” he further added: “we look forward to partnering with fosun pharma, china’s leading pharmaceutical with global competence, and strongly believe that fosun pharma will successfully develop the product and additional target adcs”.

legochem’s adc technology is the next-generation platform technology that has successfully overcome weaknesses of the first-generation adc technology, especially the stability in blood. this platform technology can be applied to a wide range of different antibody targets, which can nurture legochem’s future revenues.

under the agreement, fosun pharma will receive commercial rights in greater china area including mainland china, hong kong, macau, and taiwan, and will continue the development of the product.

legochem will receive milestones and royalties from this deal, and retains commercial rights outside of greater china area.

this deal was led by mr. chun-il park, ceo of zenith pharm, a pharmaceutical consultancy based in beijing, china.

* attached: press release.